UK - HIV Drug Intelence Approved for Use on the NHS in Scotland

The Scottish Medicines Consortium (SMC) approved Intelence (etravirine) for patients with HIV under the NHS in Scotland, in August 2009.

Tibotec’s Intelence is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), and the company claims that it is the first to show efficacy in those patients resistant to the first-generation NNRTI therapies.

Further reading - An in-depth review of the UK pharmaceutical market, including some background information on the SMC, is available from Espicom: The Pharmaceutical Market: United Kingdom (published June 2009)